As CDK1 and c-Myc are implicated in tumorigenic events and cap-dependent mRNA translation is deregulated in many cancers, this raises the potential of utilizing the mRNA capping enzymes as therapeutic targets to selectively inhibit protein synthesis in cancer cells [20,21]. This evidence concerns the gene CDK1 and cancer.